CN102327408B - Medicament for treating osteoporosis - Google Patents
Medicament for treating osteoporosis Download PDFInfo
- Publication number
- CN102327408B CN102327408B CN 201110284887 CN201110284887A CN102327408B CN 102327408 B CN102327408 B CN 102327408B CN 201110284887 CN201110284887 CN 201110284887 CN 201110284887 A CN201110284887 A CN 201110284887A CN 102327408 B CN102327408 B CN 102327408B
- Authority
- CN
- China
- Prior art keywords
- parts
- medicament
- radix
- treating osteoporosis
- rhizoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 20
- 208000001132 Osteoporosis Diseases 0.000 title abstract description 10
- 241000489492 Arisaema Species 0.000 claims abstract description 5
- 241000903946 Clematidis Species 0.000 claims abstract description 5
- 210000000941 bile Anatomy 0.000 claims abstract description 5
- 240000001972 Gardenia jasminoides Species 0.000 claims abstract description 3
- 241000725145 Homalomena Species 0.000 claims abstract description 3
- 230000001009 osteoporotic effect Effects 0.000 claims description 8
- 241000628997 Flos Species 0.000 claims description 4
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 4
- 241000180649 Panax notoginseng Species 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 3
- 241000207929 Scutellaria Species 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 abstract description 7
- 208000002193 Pain Diseases 0.000 abstract description 6
- 210000003734 kidney Anatomy 0.000 abstract description 3
- 238000005728 strengthening Methods 0.000 abstract description 2
- 244000001632 Acorus gramineus Species 0.000 abstract 1
- 241000212948 Cnidium Species 0.000 abstract 1
- 241000893536 Epimedium Species 0.000 abstract 1
- 241000208688 Eucommia Species 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 abstract 1
- 235000006753 Platycodon grandiflorum Nutrition 0.000 abstract 1
- 240000003582 Platycodon grandiflorus Species 0.000 abstract 1
- 240000004534 Scutellaria baicalensis Species 0.000 abstract 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 abstract 1
- 244000223014 Syzygium aromaticum Species 0.000 abstract 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 abstract 1
- 230000017531 blood circulation Effects 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 235000018905 epimedium Nutrition 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 239000008262 pumice Substances 0.000 abstract 1
- 229920002472 Starch Polymers 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000037182 bone density Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 208000008035 Back Pain Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- -1 absorption carrier Substances 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 201000002980 Hyperparathyroidism Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000017375 Scheuermann Disease Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 201000005311 drug allergy Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a medicament for treating osteoporosis, which is prepared from the following components in certain parts by weight: radix achyranthis bidentatae, pseudo-ginseng, epimedium, cnidium fruit, eucommia, Baikal skullcap root, cortex moutan, balloonflower, gardenia, clove, pumice, radix clematidis, rhizoma alismatis, arisaema cum bile, homalomena rhizoma and Japanese sweetflag. The medicament for treating osteoporosis has the functions of tonifying the kidney, strengthening the bone, promoting blood circulation and meridians, eliminating dampness and relieving pain, is used for preventing and treating osteoporosis, and is suitable for clinical large-scale popularization.
Description
Technical field
The present invention relates to field of medicaments, relate in particular to a kind of osteoporotic medicament for the treatment of.
Background technology
Osteoporosis (osteoporosis) is one group of osteopathia that many reasons causes, osseous tissue has normal calcification, and calcium salt and substrate are normal ratio, and the metabolic osteopathy that is reduced to characteristics with unit volume internal skeleton tissue mass becomes.In most osteoporosises, due to the minimizing of osseous tissue increases mainly due to bone absorption.Morbidity is how slowly indivedual very fast, take skeleton pain, be easy to fracture as feature biochemical analysis normal.The visible cortical bone of pathological anatomy is poor, and the sparse atrophy osteoid of bone trabecula layer is not thick.
Summary of the invention
The purpose of this invention is to provide a kind of osteoporotic medicament for the treatment of.
In order to realize purpose of the present invention, the invention provides a kind of osteoporotic medicament for the treatment of, it is to be made by the material of following weight proportioning: Radix Achyranthis Bidentatae 3-5 part, Radix Notoginseng 1-3 part, Herba Epimedii 1-3 part, Fructus Cnidii 2-5 part, Cortex Eucommiae 0.1-0.5 part, Radix Scutellariae 1-3 part, Cortex Moutan 2-5 part, Radix Platycodonis 1-3 part, Fructus Gardeniae 3-5 part, Flos Caryophylli 3-5 part, Pumex 1-3 part, Radix Clematidis 5-8 part, Rhizoma Alismatis 1-3 part, Arisaema Cum Bile 1-3 part, Rhizoma Homalomenae 3-5 part and Rhizoma Acori Graminei 1-3 part.
Preferably, the osteoporotic medicament for the treatment of of the present invention is to be made by the material of following weight proportioning: 1 part of 3 parts of Radix Achyranthis Bidentataes, 2 parts of Radix Notoginseng, 3 parts of Herba Epimedii, 2 parts of Fructus Cnidiis, 0.3 part of the Cortex Eucommiae, 2 parts of Radix Scutellariaes, 4 parts of Cortex Moutans, 2 parts of Radix Platycodoniss, 4 parts of Fructus Gardeniaes, 3 parts of Flos Caryophyllis, 2 parts of Pumexs, 6 parts of Radix Clematidis, 2 parts of Rhizoma Alismatis, 2 parts of Arisaema Cum Bile, 4 parts of Rhizoma Homalomenaes and Rhizoma Acori Graminei.
Preferably, medicament of the present invention can be tablet, dispersible tablet, capsule or decoction.Can adopt method well known to those skilled in the art to carry out the preparation of medicament.As required, can add various pharmaceutically acceptable carriers.Described carrier comprises diluent, excipient, filler, binding agent, wetting agent, disintegrating agent, absorption enhancer, surfactant, absorption carrier, lubricant of pharmaceutical field routine etc.Medicament of the present invention in the preparation, selectable filler has: starch, Icing Sugar, calcium phosphate, dextrin, microcrystalline Cellulose, lactose, pregelatinized Starch, mannitol etc.; Selectable binding agent has: sodium carboxymethyl cellulose, PVP-K30, hydroxypropyl cellulose, starch slurry, methylcellulose, ethyl cellulose, hydroxypropyl emthylcellulose, gelling starch etc.; Selectable disintegrating agent has: dried starch, polyvinylpolypyrrolidone, cross-linking sodium carboxymethyl cellulose, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose etc.; Selectable lubricant has: magnesium stearate, Pulvis Talci, sodium lauryl sulphate, micropowder silica gel etc.
The osteoporotic medicament for the treatment of of the present invention has the effect of invigorating the kidney and strengthening the bones, Huoxue San " network, damp-clearing pain-relieving, is used for prevention and treatment osteoporosis, is suitable for clinically large-scale promotion.
The specific embodiment
Further specify the present invention below by embodiment.It should be understood that embodiments of the invention are for explanation the present invention rather than limitation of the present invention.Essence according to the present invention all belongs to the scope of protection of present invention to the simple modifications that the present invention carries out.Except as otherwise noted, otherwise the percent among the present invention is percetage by weight.
Embodiment
Take by weighing Radix Achyranthis Bidentatae 30 grams, Radix Notoginseng 20 grams, Herba Epimedii 30 grams, Fructus Cnidii 20 grams, the Cortex Eucommiae 3 grams, Radix Scutellariae 20 grams, Cortex Moutan 40 grams, Radix Platycodonis 20 grams, Fructus Gardeniae 40 grams, Flos Caryophylli 30 grams, Pumex 20 grams, Radix Clematidis 60 grams, Rhizoma Alismatis 20 grams, Arisaema Cum Bile 20 grams, Rhizoma Homalomenae 40 grams and Rhizoma Acori Graminei 10 grams, pulverize, cross 80 mesh sieves.Then take by weighing Icing Sugar 50 grams, cross 80 mesh sieves, and above-mentioned raw materials mixes.Make binding agent soft material processed with the HPMC aqueous solution of 3 % by weight, granulate (granulating two times with 16 order nylon mesh), dry 2-3 individual hour under 60 ℃, with 16 purpose nylon mesh granulate.The magnesium stearate that adds again carboxymethyl starch sodium and 1 gram of 50 grams, mixing, 100 of the drift tablettings of usefulness diameter 14mm.
Experimental example
One, patient's data
1.2.1 diagnostic criteria is with reference to " Chinese's osteoporosis suggestion diagnostic criteria (the second original text) ", must possess whole body pain, be that obviously microtrauma can cause fracture mainly with lumbar and back pain, or the scheuermann kyphosis deformity, or bone density (BMD) reduces by 2 the above person of standard deviation rivers.
1.2.2 1. inclusive criteria has typical OP clinical symptoms, meets the OP diagnostic criteria; 2. the age is 45-70 person between year; 3. voluntarily as study subject, signature Informed Consent Form, and energy reception test pharmaceutical dosage form guarantee to finish person's course for the treatment of.
1.2.3 1. exclusion standard has secondary osteoporosis and other serious complication persons such as hyperparathyroidism, osteomalacia, rheumatoid arthritis, multiple myeloma; 2. present obvious bow-backed deformity, deformity and disability person; 3. suffers from the severe cardiac cerebrovascular, liver, kidney, lung and hemopoietic system primary disease person; 4. within the observation period course for the treatment of because a variety of causes, as go out, residence migration etc. can not obtain the person of following up a case by regular visits on request; 5. to this drug allergy person or to the multi-medicament allergy sufferers; 6. psychosis or patients with Alzheimer disease; 7. duration of test is failed in accordance with regulations medication or the person of dropping by the wayside.
Choose patient's 50 examples according to above-mentioned standard, male 25 examples wherein, women 25 examples, 50 years old mean age.
Two, Therapeutic Method
The preparation tablet is treated for above-mentioned patient among the use embodiment 1, and one day twice, each a slice.Take 30 days as a course for the treatment of, carry out continuously two courses for the treatment of.
Three, criterion of therapeutical effect
According to the Zheng Xiao cornel. new Chinese medicine guideline of clinical investigations (trying) (s) Beijing: Chinese Medicine science and technology publishing house, 2002; 357-358. formulate criterion of therapeutical effect.Produce effects: the pain complete obiteration, BMD checks and shows that bone density increases; Effectively: pain is obviously alleviated, and BMD checks that having no bone density descends; Invalid: relatively front with treatment, each side is all without improving.
Four, result
50 routine patients all meet the produce effects standard after treatment.
Five, untoward reaction
In therapeutic process, carry out tracing observation for 50 routine patients, do not find obvious untoward reaction.
Claims (2)
1. treat osteoporotic medicament for one kind, it is characterized in that it is to be made by the material of following weight proportioning: 1 part of 3 parts of Radix Achyranthis Bidentataes, 2 parts of Radix Notoginseng, 3 parts of Herba Epimedii, 2 parts of Fructus Cnidiis, 0.3 part of the Cortex Eucommiae, 2 parts of Radix Scutellariaes, 4 parts of Cortex Moutans, 2 parts of Radix Platycodoniss, 4 parts of Fructus Gardeniaes, 3 parts of Flos Caryophyllis, 2 parts of Pumexs, 6 parts of Radix Clematidis, 2 parts of Rhizoma Alismatis, 2 parts of Arisaema Cum Bile, 4 parts of Rhizoma Homalomenaes and Rhizoma Acori Graminei.
2. the osteoporotic medicament for the treatment of according to claim 1 is characterized in that, described medicament is tablet, capsule or decoction.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110284887 CN102327408B (en) | 2011-09-23 | 2011-09-23 | Medicament for treating osteoporosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110284887 CN102327408B (en) | 2011-09-23 | 2011-09-23 | Medicament for treating osteoporosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102327408A CN102327408A (en) | 2012-01-25 |
| CN102327408B true CN102327408B (en) | 2013-03-13 |
Family
ID=45479539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110284887 Expired - Fee Related CN102327408B (en) | 2011-09-23 | 2011-09-23 | Medicament for treating osteoporosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102327408B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103006983A (en) * | 2012-12-06 | 2013-04-03 | 南通市华东润滑设备有限公司 | Traditional Chinese medicine for treating osteoporosis |
| CN105998461A (en) * | 2016-06-08 | 2016-10-12 | 石良 | Pill for treating rarefaction of bones and preparation and taking method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101450167A (en) * | 2007-12-07 | 2009-06-10 | 李勇 | Medicine composition for treating osteoporosis |
| CN101708266A (en) * | 2009-12-14 | 2010-05-19 | 张晨 | Oral herbal decoction for treating osteoporosis |
-
2011
- 2011-09-23 CN CN 201110284887 patent/CN102327408B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101450167A (en) * | 2007-12-07 | 2009-06-10 | 李勇 | Medicine composition for treating osteoporosis |
| CN101708266A (en) * | 2009-12-14 | 2010-05-19 | 张晨 | Oral herbal decoction for treating osteoporosis |
Non-Patent Citations (2)
| Title |
|---|
| 王剑等.补肾、健脾、活血中药对糖皮质激素性骨质疏松症大鼠骨组织Osterix mRNA及蛋白表达的影响.《中华中医药杂志》.2011,(第04期), |
| 补肾、健脾、活血中药对糖皮质激素性骨质疏松症大鼠骨组织Osterix mRNA及蛋白表达的影响;王剑等;《中华中医药杂志》;20110430(第04期);第801-805页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102327408A (en) | 2012-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1051237C (en) | Meicinal prepn. "Kexianling" for curing epilepsy | |
| CN102319332A (en) | Musk bone reunion Chinese medicinal composition | |
| CN101530579B (en) | A pharmaceutical composition for soothing the nerves | |
| CN102327408B (en) | Medicament for treating osteoporosis | |
| CN101181488A (en) | Chinese medicine composition orally taken for curing osteosporosis | |
| CN101284108B (en) | Traditional Chinese medicine combination for curing lumbar disease | |
| CN101095730A (en) | Medicine for treating rheumatism atrophic arthritis | |
| CN1872308A (en) | Preparation of Chinese traditional medicine for treating pulmonary tuberculosis | |
| CN102657751B (en) | Medicament for treating osteoporosis | |
| CN100344318C (en) | Medicine for treating apoplectic sequel and prepn. thereof | |
| CN103394069B (en) | Traditional Chinese medicine composition for treating ankylosing spondylitis and preparation method thereof | |
| CN103735830B (en) | One is treated osteoporotic Chinese medicine composition | |
| CN103191315B (en) | Traditional Chinese medicine for treating postmenopausal osteoporosis | |
| CN103157084A (en) | Drug for treating osteoporosis | |
| CN102274423B (en) | Medicament for treating anxiety | |
| CN106511549A (en) | Traditional Chinese medicine composition containing millettia specisoa and preparation method of traditional Chinese medicine composition | |
| CN102526473B (en) | Medicament for treating chronic virus B hepatitis | |
| CN1723933A (en) | Traditional Chinese medicine capsule for treating application, and its prodn. method | |
| CN1313120C (en) | Application of ciliate bugle herb piece in preparing medicine for treating scapulohumeral periarthritis | |
| CN1150921C (en) | Medicine for treating algia disease and its preparing process | |
| CN102657771A (en) | Medicament for osteoporosis treatment | |
| CN102641418B (en) | Medicament for treating migraine | |
| CN1562117A (en) | Chinese medicinal preparation for quick bone fracture setting | |
| CN1062151C (en) | Medicinal compsn. for treatment of spur and its prepn. | |
| CN104606441A (en) | Traditional Chinese medicine composition for treating postmenopausal osteoporosis caused by deficiency of the kidney-yang |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: TIANJIANG PHARMACEUTICAL INDUSTRY CO., LTD., JIANG Free format text: FORMER OWNER: TANG AILING Effective date: 20130802 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 272100 JINING, SHANDONG PROVINCE TO: 214400 WUXI, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20130802 Address after: 214400 Jiangyin Economic Development Zone, Jiangsu, Qin Shan Road, No. 8 Patentee after: Tianjiang Pharmaceutical Industry Co., Ltd., Jiangyin Address before: 272100 Shandong province Jining City Road No. 28, Department of Orthopaedics Hospital Pharmacy Patentee before: Tang Ailing |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| CB02 | Change of applicant information |
Inventor after: Shen Xiangming Inventor before: Tang Ailing |
|
| COR | Change of bibliographic data | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20161216 Address after: Room 2388, building, No. 200120 Pu Pu Road, Shanghai, Pudong New Area, China, A1 Patentee after: SHANGHAI MINGHONG BIOENGINEERING CO., LTD. Address before: 214400 Jiangyin Economic Development Zone, Jiangsu, Qin Shan Road, No. 8 Patentee before: Jiangyin Tianjiang Pharmacy Group Co., Ltd. |
|
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: SHANGHAI MINGHONG BIO-ENGINEERING Co.,Ltd. Document name: Notification to Pay the Fees |
|
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: Patent director of Shanghai Minghong Bioengineering Co., Ltd Document name: Notification of Termination of Patent Right |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130313 Termination date: 20190923 |